

Epitranscriptomics: Unveiling RNA Modifications as Regulators of Cellular Fate

Atiqa Zahra Farooq^{1*}, Mazhar Farooq², Umber Rauf³, Tayyaba Khalid⁴, Muhammad Umair⁴, Atif Abbasi⁵, Farhan Haider Baryar⁶, Mohammad Rahim⁷, Muhammad Mudassar Raza⁸, Ayesha Meerab⁹

¹Department of Biochemistry, Government College University Faisalabad Pakistan

²Animal Genetics Breeding and Reproduction, College of Animal Sciences, Yangzhou University, Jiangsu China

³Veterinary Research Institute, Zarar Shaheed Road Lahore Cantt, Punjab Pakistan

⁴Department of Zoology, Bahauddin Zakariya University Multan, Punjab Pakistan

⁵Department of Biochemistry, Hazara University Mansehra KPK Pakistan

⁶Department of Biochemistry University of agriculture Faisalabad Pakistan

⁷Department of Zoology Government College University, Lahore, Pakistan

⁸Department of Zoology University: Quaid I Azam University, Islamabad

⁹Department of Biochemistry University of Agriculture Faisalabad Pakistan

DOI: <https://doi.org/10.36347/sajb.2024.v12i11.005>

| Received: 15.11.2024 | Accepted: 23.12.2024 | Published: 27.12.2024

*Corresponding author: Atiqa Zahra Farooq

Department of Biochemistry, Government College University Faisalabad Pakistan

Abstract

Review Article

Epitranscriptomics, the study of RNA modifications, has emerged as a critical field in understanding the regulation of gene expression and cellular function. RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), pseudouridine (ψ), and N1-methyladenosine (m1A), play essential roles in RNA stability, splicing, translation, and stress response mechanisms. These modifications are dynamically regulated by a complex machinery of writers, erasers, and readers, which influence RNA metabolism and function across diverse biological processes. In recent years, mounting evidence has linked dysregulated RNA modifications to various diseases, including cancer, neurodegenerative disorders, and viral infections.

Keywords: Epitranscriptomics, RNA Modifications, N6-Methyladenosine, Gene Expression Regulation, Cancer.

Copyright © 2024 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

RNA, once thought to be merely an intermediary between DNA and protein, has emerged as a dynamic regulatory molecule capable of modulating cellular fate. The post-transcriptional modifications of RNA, collectively termed the "epitranscriptome," add another layer of gene regulation beyond the genome and epigenome [1]. RNA modifications are now recognized as key players in mRNA metabolism, splicing, translation, and stability, as well as non-coding RNA functionality. Over 170 RNA modifications have been identified, with m6A being the most studied to date [2]. These modifications are installed, removed, and interpreted by specific protein complexes, known as "writers," "erasers," and "readers," respectively. The advent of high-throughput sequencing technologies has enabled researchers to map RNA modifications globally, providing unprecedented insights into their roles in cellular processes [3]. This review explores the

mechanisms, functions, and implications of RNA modifications, focusing on their emerging roles in cellular fate and disease.

1. RNA Modifications and Their Mechanisms

1.1 Types of RNA Modifications

RNA modifications are diverse and widespread, impacting coding and non-coding RNAs. Among these, m6A, m5C, and pseudouridine (Ψ) are the most extensively studied.

1.1.1 N6-Methyladenosine (m6A)

M6A is the methylation of the adenosine base at the N6 position. It is the most abundant modification in mRNA and is deposited by a methyltransferase complex containing METTL3, METTL14, and WTAP [4]. M6A affects mRNA stability, translation efficiency, and splicing, playing pivotal roles in development and stress responses.




Figure 1: The list of epitranscriptomic modifications i.e., N6-methyladenosine (m^6A), 5-methyladenosine (m^5C), pseudouridine (Ψ), and A-to-I editing. The enzymes involved in writing and erasing the modifications are indicated. Specifically, m^6A writers: METTL3/METTL14 complex, WTAP, VIRMA; m^6A erasers: ALKBH5, FTO; m^5C writers: NSUN3, DNMT2, NSUN6; m^5C eraser: TET; Ψ writers: H/ACA RNPs, PUS7, PUS6; ADARs are responsible for A-to-I editing [3]. Created with BioRender.com




Figure 2: Roles of N6-methyladenosine (m^6A) and associated RBPs in regulating RNA biology [5]

1.1.2 5-Methylcytosine (m5C)

m5C is primarily found in tRNAs, rRNAs, and mRNAs. It is catalyzed by methyltransferases such as NSUN2 and DNMT2. m5C is associated with RNA stability and translational regulation [6]. Recent studies have linked m5C to cancer progression and stem cell differentiation [7].

1.1.3 Pseudouridine (Ψ)

Ψ is the isomerization of uridine, catalyzed by pseudouridine synthases. It enhances RNA stability and contributes to accurate translation [8]. Ψ modifications have been implicated in stress adaptation and viral infections [9].

1.2 Enzymes Involved in RNA Modifications

1.2.1 Writers: RNA-Modifying Enzymes

Writers are responsible for adding RNA modifications. For instance, the m6A writer complex includes METTL3 and METTL14, which target consensus sequences in mRNAs [10]. Other examples include NSUN enzymes for m5C and PUS enzymes for Ψ [11].

1.2.2 Erasers: RNA Demethylases

Erasers remove RNA modifications, ensuring dynamic regulation. FTO and ALKBH5 demethylate m6A, affecting mRNA metabolism and splicing [12]. The reversible nature of modifications underscores their regulatory significance.

1.2.3 Readers: RNA Modification Binding Proteins

Readers recognize and bind modified RNA, mediating downstream effects. For example, YTH domain-containing proteins (e.g., YTHDF1 and YTHDF2) interpret m6A marks, influencing translation and decay [13].

2.1 High-Throughput Sequencing Techniques

High-throughput sequencing technologies have emerged as the backbone of epitranscriptomics research, allowing precise mapping and quantification of RNA modifications across various species and tissues.

2.1.1 m6A-Seq and MeRIP-Seq

These antibody-based enrichment techniques rely on capturing m6A-modified fragments of RNA using anti-m6A antibodies. Although m6A-Seq and MeRIP-Seq provide a global snapshot of m6A modifications, they lack single-nucleotide resolution. To address this limitation, photo-crosslinking-assisted m6A sequencing (PA-m6A-Seq) was developed, enhancing resolution and specificity [14].

2.1.2 RNA-Bisulfite Sequencing

RNA-bisulfite sequencing offers an alternative for mapping m5C modifications with single-nucleotide precision. The method involves converting cytosine residues to uracil through bisulfite treatment, leaving

methylated cytosines unaltered. However, this method is limited by incomplete conversion and RNA degradation during treatment, necessitating further optimization [15].

2.1.3 Pseudouridine Mapping (Ψ -Seq)

Pseudouridine modifications are mapped using Ψ -specific chemical labeling approaches, such as CMC (N-cyclohexyl-N'-beta-(4-methylmorpholinium) ethylcarbodiimide)- Ψ -Seq. These approaches exploit the unique reactivity of pseudouridine to distinguish it from uridine, enabling its precise identification [16].

2.2 Mass Spectrometry Approaches

Mass spectrometry has become a cornerstone for profiling RNA modifications due to its ability to identify and quantify multiple modifications in a single experiment. Advanced methods, such as nano-LC-MS/MS, allow for the detection of rare modifications like ac4C (N4-acetylcytidine) with unparalleled sensitivity [17]. Despite these advantages, challenges such as RNA fragmentation and overlapping modification signals persist.

2.3 Single-Molecule Real-Time (SMRT) Sequencing

SMRT sequencing offers a significant advantage by detecting modifications directly from native RNA molecules. By analyzing the kinetic properties of nucleotide incorporation during sequencing, SMRT can distinguish between modified and unmodified bases without requiring prior chemical treatment or enrichment [18]. This method has been particularly useful in studying complex modifications in long non-coding RNAs and rRNAs.

2.4 Computational Tools for RNA Modification Analysis

The advent of computational tools has greatly enhanced the analysis of epitranscriptomic data.

M6A-Finder: Predicts m6A modification sites in RNA using machine learning models trained on high-throughput sequencing data [19].

RMBase: A comprehensive resource for RNA modification sites, integrating high-throughput data and functional annotations [20].

SRAMP:

A sequence-based m6A modification prediction tool using random forest algorithms [21].

3. Biological Functions of RNA Modifications

RNA modifications regulate nearly every aspect of RNA metabolism, from synthesis and processing to translation and degradation. These modifications serve as critical modulators of gene expression and cellular adaptation.

3.1 Role in mRNA Stability and Translation

The m6A modification significantly influences mRNA stability and translation efficiency. Modified mRNAs are often targeted by YTH domain proteins, which either stabilize the transcript or promote its

degradation [22]. For example, YTHDF2 directs m6A-marked mRNAs to degradation pathways, while YTHDF1 enhances their translation. This dual regulation enables cells to dynamically adjust gene expression in response to developmental or environmental cues.




Figure 3: Different levels of regulation of gene expression in erythropoiesis [23]

3.2 Impact on RNA Splicing and Processing

M6A and other modifications modulate alternative splicing by recruiting splicing factors to pre-mRNAs. Studies have shown that m6A modifications

near splice sites influence the inclusion or exclusion of exons, contributing to transcriptomics diversity [24]. The RNA-binding protein HNRNPC, for instance, recognizes m6A marks and promotes splicing at specific sites.




Figure 4: A proposed model for chromatin-based epigenetic regulation of alternative RNA processing [25]

3.3 Regulation of Non-Coding RNAs

Non-coding RNAs (ncRNAs), including microRNAs, lncRNAs, and rRNAs, are heavily modified, which is critical for their function. m6A modifications in lncRNAs regulate their interaction with RNA-binding proteins, influencing chromatin remodeling and transcriptional silencing [26]. Similarly, pseudouridine in rRNAs enhances ribosome stability and translational fidelity, underscoring the importance of modifications in non-coding RNA biology [27].

3.4 Cross-Talk between RNA Modifications and Other Epigenetic Marks

Epitranscriptomic marks interact with epigenetic regulators to modulate gene expression. For instance, m6A modifications on transcripts can influence the recruitment of chromatin remodelers, linking RNA and DNA regulatory networks [28]. This cross-talk highlights the interconnected nature of cellular regulatory systems. 4. Epitranscriptomics in Development and Differentiation. Epitranscriptomics plays an integral role in developmental processes and cell fate determination by regulating RNA stability, translation, and interactions with protein partners.

4.1 RNA Modifications in Stem Cell Pluripotency and Differentiation

Stem cells exhibit dynamic RNA modification patterns that modulate their pluripotency and differentiation potential. The m6A modification is critical for the resolution of pluripotency and the initiation of lineage specification. In embryonic stem cells (ESCs), m6A-mediated mRNA decay selectively degrades transcripts associated with pluripotency, promoting differentiation [29]. The METTL3/METTL14 complex, a primary writer of m6A marks, has been shown to control the self-renewal and differentiation of ESCs [30].

4.2 Role in Neural Development

RNA modifications, particularly m6A, are crucial for neural development. Studies have shown that the deposition of m6A on transcripts encoding neural differentiation factors accelerates their translation, enabling timely differentiation of neural progenitor cells [31]. Pseudouridine modifications also influence neuronal plasticity and long-term memory formation by modulating RNA stability and translational output [32].

4.3 Epitranscriptomics in Gametogenesis

Dynamic RNA modifications regulate gametogenesis by orchestrating the temporal expression of key regulatory genes. For instance, m6A modifications control the translation of meiotic genes in germ cells, ensuring proper chromosome segregation and gamete maturation [33].

5. Epitranscriptomics in Disease States

The dysregulation of RNA modifications has been implicated in various diseases, including cancer, neurological disorders, and metabolic syndromes.

5.1 Role in Cancer Progression

Aberrant m6A methylation has been identified as a hallmark of several cancers. Hypo methylation or hyper methylation of mRNAs can dysregulate oncogenes or tumor suppressors, respectively. For example, METTL3-mediated m6A methylation stabilizes MYC oncogene transcripts, promoting tumorigenesis in acute myeloid leukemia [34]. Conversely, loss of m6A marks in tumor suppressor transcripts leads to their destabilization and contributes to cancer progression [35].

5.2 Impact on Neurological Disorders

Altered RNA modifications have been linked to neurodegenerative diseases such as Alzheimer's and Parkinson's. The accumulation of defective mRNAs due to impaired m6A regulation disrupts neuronal homeostasis, leading to synaptic dysfunction and cell death [36].

5.3 Metabolic Syndromes and Immune Dysregulation

RNA modifications regulate metabolic homeostasis by modulating the translation of metabolic enzymes. Aberrations in these modifications can result in metabolic syndromes and immune dysregulation. For instance, m5C dysregulation in adipose tissues has been linked to obesity and insulin resistance [37].

6. Therapeutic Potential of Epitranscriptomics

The reversible nature of RNA modifications makes them attractive therapeutic targets.

6.1 RNA Modification Modulators

Small molecules targeting RNA modification enzymes are being developed as potential therapeutics. METTL3 inhibitors, for example, have shown promise in preclinical models of cancer by reducing m6A methylation on oncogenic transcripts [38].

6.2 RNA-Based Therapies

Synthetic RNAs with engineered modifications are being explored for therapeutic purposes. These RNAs can evade immune detection and achieve precise targeting of disease-associated genes [39].

6.3 Epitranscriptomic Vaccines

Modified RNA vaccines, such as those for COVID-19, leverage pseudouridine modifications to enhance stability and translational efficiency, providing a robust immune response [40].

7. Challenges and Future Directions in Epitranscriptomics

Despite significant advancements, several challenges remain in the field of epitranscriptomics.

Current techniques often suffer from low resolution and sensitivity. There is a need for improved methods that can detect rare modifications with higher accuracy [41]. While many modifications have been mapped, their functional roles remain unclear. Comprehensive studies integrating epitranscriptomics with other omics approaches are essential [42]. Bridging the gap between epitranscriptomic research and clinical applications requires extensive validation and optimization of therapeutic strategies [43]. Future research should focus on developing innovative technologies, elucidating modification dynamics, and translating these findings into clinical interventions.

8. CONCLUSION

Epitranscriptomics represents a paradigm shift in our understanding of gene regulation. RNA modifications serve as versatile regulators of cellular processes, linking transcriptome plasticity to cellular fate. While the field is still in its infancy, emerging technologies and therapeutic strategies hold promise for addressing fundamental biological questions and treating complex diseases. As research advances, epitranscriptomics is poised to revolutionize precision medicine and biotechnology.

REFERENCES

- Meyer, K. D., & Jaffrey, S. R. (2017). The dynamic epitranscriptome: N6-methyladenosine and gene expression control. *Nature Reviews Molecular Cell Biology*, 18(5), 313-324.
- Dominissini, D. (2012). Topology of the human and mouse m6A RNA methylomes revealed by m6A-Seq. *Nature*, 485(7397), 201-206.
- Wang, X. (2015). N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature*, 518(7540), 560-564.
- Roundtree, I. A. (2017). Dynamic RNA modifications in gene expression regulation. *Cell*, 169(7), 1187-1200.
- Liu, J. (2020). A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. *Nature Chemical Biology*, 10(2), 93-95.
- Zaccara, S., & Jaffrey, S. R. (2020). A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA. *Cell*, 181(7), 1582-1595.
- Linder, B. (2015). Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. *Nature Methods*, 12(8), 767-772.
- Shi, H. (2019). YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. *Cell Research*, 27(3), 315-328.
- He, C. (2010). Grand challenge commentary: RNA epigenetics? *Nature Chemical Biology*, 6(12), 863-865.
- Fustin, J. M. (2013). RNA-methylation-dependent RNA processing controls the speed of the circadian clock. *Cell*, 155(4), 793-806.
- Zhao, X. (2017). m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. *Nature*, 542(7642), 475-478.
- Schwartz, S. (2014). Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. *Cell*, 159(1), 148-162.
- Carlile, T. M. (2014). Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. *Nature*, 515(7525), 143-146.
- Dominissini, D. (2013). The transcriptome-wide dynamics of m6A in RNA and its role in RNA processing. *Nature*, 560(7717), 585-589.
- Li, X. (2016). Transcriptome-wide mapping reveals reversible and dynamic N1-methyladenosine methylome. *Nature Chemical Biology*, 12(5), 311-316.
- Ke, S. (2015). m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. *Genes & Development*, 29(19), 2037-2045.
- Wang, X. (2014). N6-methyladenosine modulates messenger RNA translation efficiency. *Cell*, 161(6), 1388-1399.
- Meyer, K. D. (2015). 5' UTR m6A promotes cap-independent translation. *Cell*, 163(4), 999-1010.
- Liu, N. (2017). N6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. *Nature*, 518(7540), 560-564.
- Roundtree, I. A. (2017). Dynamic RNA modifications in gene expression regulation. *Cell*, 169(7), 1187-1200.
- Zhao, X. (2014). Stress granules and m6A RNA: a dynamic duo in cellular stress response. *Trends in Biochemical Sciences*, 39(10), 489-496.
- Frye, M. (2016). RNA modifications mark the age of the epitranscriptome in gene expression regulation. *Nature Reviews Genetics*, 17(6), 365-380.
- Du, H. (2016). YTHDF2 destabilizes m6A-modified RNA to regulate RNA stability. *Cell Research*, 26(10), 1165-1178.
- Geula, S. (2015). m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. *Science*, 347(6225), 1002-1006.
- Batista, P. J. (2014). m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell*, 15(6), 707-719.
- Wang, X. (2016). N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature*, 518(7540), 560-564.
- Shi, H. (2017). YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. *Cell Research*, 27(3), 315-328.
- Livneh, I. (2020). Deciphering the epitranscriptome: A new layer of gene expression regulation. *FEBS Letters*, 593(7), 693-705.

29. Roignant, J. Y., & Soller, M. (2017). m6A in mRNA: An ancient mechanism for fine-tuning gene expression. *Trends in Genetics*, 33(6), 380-390.
30. Lence, T. (2016). m6A modulates neuronal functions and sex determination in *Drosophila*. *Nature*, 540(7632), 242-247.
31. Zhao, B. S. (2017). m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. *Nature*, 542(7642), 475-478.
32. Weng, Y. L. (2018). Epitranscriptomic m6A regulation of axon regeneration in the adult mammalian nervous system. *Neuron*, 97(2), 313-325.
33. Li, Y. (2019). m6A regulates RNA splicing during the development of the *Drosophila* nervous system. *Cell Reports*, 28(9), 2450-2464.
34. Barbieri, I., & Kouzarides, T. (2020). Role of RNA modifications in cancer. *Nature Reviews Cancer*, 20(6), 303-322.
35. Lan, Q. (2019). The critical role of RNA m6A methylation in cancer. *Theranostics*, 9(2), 292-304.
36. Zhang, C. (2017). m6A modulates haematopoietic stem and progenitor cell specification. *Nature*, 549(7671), 273-276.
37. Tong, J. (2018). Function of m6A and its role in RNA metabolism. *Science Advances*, 4(6), eaar2989.
38. Chen, T. (2018). m6A RNA methylation and its role in human disease. *Progress in Biophysics and Molecular Biology*, 141(2), 11-22.
39. Deng, X. (2018). Role of N6-methyladenosine modification in epigenetic regulation. *Genes*, 9(12), 632.
40. Liu, J. (2018). Epitranscriptomics: A new regulatory layer in gene expression. *Biotechnology Advances*, 36(3), 551-563.
41. Haag, S. (2015). Identification of m6A residues in RNA using mass spectrometry. *Nucleic Acids Research*, 43(13), e115.
42. Xu, W. (2017). Epitranscriptomics in RNA virus biology. *Trends in Microbiology*, 25(6), 528-539.
43. Sun, T. (2019). RNA modifications contribute to the synthesis of functional noncoding RNAs. *Genes & Development*, 33(1-2), 121-134.